Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Epilepsy
•
Neurology
When do you consider switching a generic formulation antiseizure medication to the brand formulation?
Related Questions
How does a patient’s BASED score after starting infantile spasms therapy guide your treatment plan?
How do you approach use of newer anti-seizure medications for epilepsy patients on DOACs?
When would you consider using vigabatrin as part of treatment for status epilepticus?
Does persistent focal slowing without epileptiform discharges indicate increased seizure risk in patients without significant structural abnormalities?
How do you adjust the loading and maintenance doses for Keppra when treating status epilepticus in patients with ESRD, patients on HD, or patients on CVVH?
If a patient who has previously been taking lamotrigine stops taking it for between two weeks and a month, do you have to uptitrate it all over again or do you have another way to resume it?
How do you utilize at-home seizure monitoring devices for your patients with epilepsy?
How are you using CSF cytokine panels in autoimmune encephalitis, if at all?
When do you consider long-term anti-seizure medication for patients who have an acute symptomatic seizure in the setting of a cerebrovascular event?
When do you consider ketamine to treat nonconvulsive status epilepticus?
